Get started
Author

Juan María Vázquez Morón

Observed names: J M Vázque morón, J M Vázquez Morón, J M Vázquez-Morón, J. M. Vázquez-Morón, JM Vázquez Morón, Juan María Vázquez-Morón
ORCID: 0000-0003-3168-791X
Observed ORCID: 0000-0003-3168-791X
OpenAlex ID: A5003967216
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study
2022 · María Chaparro, Iria Baston-Rey, et al. · Inflammatory Bowel Diseases · 70
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety
2022 · María Chaparro, Diana Acosta, et al. · The American Journal of Gastroenterology · 36
Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease
2019 · M Chaparro, A Garre, et al. · Journal of Crohn s and Colitis · 34
PDF
Crohn's-like disease in a patient with common variable immunodeficiency treated with azathioprine and adalimumab
2013 · Juan María Vázquez-Morón, Héctor Pallarés-Manrique, et al. · Revista Española de Enfermedades Digestivas · 30
PDF
Prognosis of Patients with Ulcerative Colitis in Sustained Remission After Thiopurines Withdrawal
2015 · Estefanía Moreno-Rincón, José Manuel Benítez, et al. · Inflammatory Bowel Diseases · 28
Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn’s disease with fecal calprotectin
2017 · Juan María Vázquez Morón, Héctor Pallarés Manrique, et al. · Revista Española de Enfermedades Digestivas · 22
The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?
2019 · Rafael Rodríguez Moncada, Juan María Vázquez Morón, et al. · Revista Española de Enfermedades Digestivas · 20
Ustekinumab in Crohn's disease: real-world outcomes and predictors of response.
2020 · Laura Lorenzo González, Teresa Valdés Delgado, et al. · Revista Española de Enfermedades Digestivas · 18
PDF
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months
2018 · María Fernanda Guerra Veloz, Juan María Vázquez Morón, et al. · Revista Española de Enfermedades Digestivas · 18
Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia
2022 · Alvaro Hernández Martínez, Pilar Navajas Hernández, et al. · Revista Española de Enfermedades Digestivas · 14
PDF
P744 Safety of live vaccines in children exposed to biological agents for inflammatory bowel disease (IBD) in utero or during breastfeeding
2023 · M Chaparro, M García Donday, et al. · Journal of Crohn s and Colitis · 11
PDF
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
2022 · María Chaparro, Iria Baston-Rey, et al. · Journal of Clinical Medicine · 10
Effectiveness and safety of ustekinumab dose escalation in Crohn�s disease: a multicenter observational study
2023 · Raúl Vicente Olmedo Martín, Juan María Vázquez Morón, et al. · Revista Española de Enfermedades Digestivas · 7
PDF
Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
2019 · María Chaparro, María G. Donday, et al. · Therapeutic Advances in Gastroenterology · 7
Managing iron deficiency and iron deficiency anemia in inflammatory bowel disease. The results of the “Gestiona hierro-EII” survey
2018 · Francesc Casellas Jordá, Isabel Vera Mendoza, et al. · Revista Española de Enfermedades Digestivas · 6
Intravenous ustekinumab reinduction as a Crohn�s disease rescue strategy following a secondary non-response
2019 · Juan María Vázquez Morón, Rafael Rodríguez Moncada, et al. · Revista Española de Enfermedades Digestivas · 5
Psychomotor Development in Infants Following Maternal Exposure to Biologics: Results From the DUMBO Registry
2025 · Laura Palomino, Marta Velasco Rodríguez-Belvís, et al. · Clinical Gastroenterology and Hepatology · 3
P545 Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU
2022 · M Chaparro, A Gutiérrez, et al. · Journal of Crohn s and Colitis · 2
P762 Onset of inflammatory bowel disease during treatment with secukinumab: Can anti-IL-17A be a trigger for inflammatory bowel disease?
2019 · R Rodríguez Moncada, J M Vázquez Morón, et al. · Journal of Crohn s and Colitis · 2
DOP038 Impact of prenatal and breastfeeding exposure to biologic drugs on the first-year anthropometric development of infants born to mothers with inflammatory bowel disease from DUMBO registry of GETECCU
2025 · L Palomino, M Velasco Rodríguez-Belvís, et al. · Journal of Crohn s and Colitis · 1
P675 Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, safety and impact of extraintestinal manifestations and immunomediated diseases
2023 · M Chaparro, D Acosta, et al. · Journal of Crohn s and Colitis · 1
P373 Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, impact of extraintestinal manifestations and immunomediated diseases and safety
2022 · M Chaparro, D Acosta, et al. · Journal of Crohn s and Colitis · 1
P263 Influence of Crohn′s Disease phenotype in the retention rate of ustekinumab treatment: SUSTAIN Study
2021 · M Chaparro, I Bastón Rey, et al. · Journal of Crohn s and Colitis · 1
PDF
P478 Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy: an observational multicentre study
2021 · R Olmedo-Martín, M D M Martín-Rodríguez, et al. · Journal of Crohn s and Colitis · 1
Comparative study between different methods for the determination of fecal calprotectin
2021 · Rocio Cabra-Rodríguez, Miguel Ángel Castaño López, et al. · Revista de Medicina de Laboratorio · 1
PDF
Works count: 56
Citation count: 355
H-index: 11
I10-index: 12
Year
Topic
Type